Evidence map›Paper›PMID 26961240›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2016

Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.

Chris D Bostick, Katherine M Hickey, Lance A Wollenberg, Darcy R Flora, Timothy S Tracy, Peter M Gannett

Open access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Chris D BostickDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.).
Katherine M HickeyDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.).
Lance A WollenbergDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.).
Darcy R FloraDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.).
Timothy S TracyDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.).
Peter M GannettDepartment of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia (C.D.B., K.M.H.); Array BioPharma, Boulder, Colorado (L.A.W.); Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (D.R.F.); College of Pharmacy, University of Kentucky, Lexington, Kentucky (T.S.T.); and Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, Florida (P.M.G.) pgannett@nova.edu.
Array BioPharma (United States) · USNova Southeastern University · USUniversity of Kentucky · USUniversity of Minnesota · USWest Virginia University · US

Funding

P450 Protein-Protein Interactions Determined by Selective Protein ManipulationR01GM086891 · NIGMS · UNIVERSITY OF MINNESOTA · PI GANNETT, PETER M., TRACY, TIMOTHY S. · 2009 to 2010
$730k
NIGMS NIH HHS R01 GM086891
6 · The paper itself

Abstract

Cytochrome P450 (P450) protein-protein interactions have been shown to alter their catalytic activity. Furthermore, these interactions are isoform specific and can elicit activation, inhibition, or no effect on enzymatic activity. Studies show that these effects are also dependent on the protein partner cytochrome P450 reductase (CPR) and the order of protein addition to purified reconstituted enzyme systems. In this study, we use controlled immobilization of P450s to a gold surface to gain a better understanding of P450-P450 interactions between three key drug-metabolizing isoforms (CYP2C9, CYP3A4, and CYP2D6). Molecular modeling was used to assess the favorability of homomeric/heteromeric P450 complex formation. P450 complex formation in vitro was analyzed in real time utilizing surface plasmon resonance. Finally, the effects of P450 complex formation were investigated utilizing our immobilized platform and reconstituted enzyme systems. Molecular modeling shows favorable binding of CYP2C9-CPR, CYP2C9-CYP2D6, CYP2C9-CYP2C9, and CYP2C9-CYP3A4, in rank order.KDvalues obtained via surface plasmon resonance show strong binding, in the nanomolar range, for the above pairs, with CYP2C9-CYP2D6 yielding the lowestKD, followed by CYP2C9-CYP2C9, CYP2C9-CPR, and CYP2C9-CYP3A4. Metabolic incubations show that immobilized CYP2C9 metabolism was activated by homomeric complex formation. CYP2C9 metabolism was not affected by the presence of CYP3A4 with saturating CPR concentrations. CYP2C9 metabolism was activated by CYP2D6 at saturating CPR concentrations in solution but was inhibited when CYP2C9 was immobilized. The order of addition of proteins (CYP2C9, CYP2D6, CYP3A4, and CPR) influenced the magnitude of inhibition for CYP3A4 and CYP2D6. These results indicate isoform-specific P450 interactions and effects on P450-mediated metabolism.

Indexed as

Cytochrome P-450 Enzyme SystemModels, MolecularNADPH-Ferrihemoprotein ReductasePharmaceutical PreparationsCytochrome P-450 Enzyme SystemNADPH-Ferrihemoprotein ReductasePharmaceutical Preparations

Identifiers

PMID26961240
PMCPMC4851305
OpenAlexW2294625644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.